Compare Freshworks Inc (FRSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Neurocrine Biosciences Inc — how do they compare? Freshworks Inc trades at $10.95 (market cap $2.93B), while Neurocrine Biosciences Inc trades at $172.01 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.9× Freshworks Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | NBIX | |
|---|---|---|
Market Cap | $2.93B | $17.30B |
Sector | Technology | Health |
52-Week High | $14.77 | $180.55 |
52-Week Low | $6.88 | $123.10 |
Enterprise Value | $2.19B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.88, up 3.92% with a bullish technical signal and strong revenue growth from $720M in 2024 to $839M in 2025. The company achieved profitability in 2025 with net income of $184M, reversing prior losses. Recent news highlights AI product launches and a key partnership with Vanquis, while analyst consensus is split evenly between Buy and Hold ratings.
The outlook is positive with accelerating revenue and a path to sustained profitability, though high EV/EBITDA of 51.08 suggests premium valuation. Risks include execution on AI initiatives and competitive pressure in SaaS. Wall Street sees 26-38% upside potential based on price targets, making FRSH an attractive growth story if margins expand as projected.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
